CN101693669B - Minocycline hydrochloride hydrate crystal forms and preparation method thereof - Google Patents
Minocycline hydrochloride hydrate crystal forms and preparation method thereof Download PDFInfo
- Publication number
- CN101693669B CN101693669B CN2009101527834A CN200910152783A CN101693669B CN 101693669 B CN101693669 B CN 101693669B CN 2009101527834 A CN2009101527834 A CN 2009101527834A CN 200910152783 A CN200910152783 A CN 200910152783A CN 101693669 B CN101693669 B CN 101693669B
- Authority
- CN
- China
- Prior art keywords
- minocycline hydrochloride
- alcohol
- crystal forms
- hydrochloride hydrate
- hydrate crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 229960002421 minocycline hydrochloride Drugs 0.000 title claims abstract description 63
- 239000013078 crystal Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000012046 mixed solvent Substances 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 238000001291 vacuum drying Methods 0.000 claims description 9
- 239000005457 ice water Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- 238000004455 differential thermal analysis Methods 0.000 claims description 3
- 238000002050 diffraction method Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 description 11
- 229960004023 minocycline Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 238000002411 thermogravimetry Methods 0.000 description 6
- -1 carboxamide hydrochloride Chemical class 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940110254 minocin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to minocycline hydrochloride hydrate crystal forms and a preparation method thereof. The invention provides two minocycline hydrochloride hydrate crystal forms, wherein an X-ray diffraction map of the crystal form A shows a characteristic diffraction peak in positions of 2 theta(DEG, +/-0.2)7.2 DEG, 7.8 DEG, 12.5 DEG, 12.8 DEG, 13.9 DEG, 15.5 DEG, 17.0 DEG, 17.5 DEG, 17.9 DEG, 18.8 DEG, 20.0 DEG, 20.8 DEG, 21.9 DEG, 22.3 DEG, 23.3 DEG, 24.3 DEG, 25.0 DEG, 26.8 DEG, 27.3 DEG, 29.5 DEG, 31.4 DEG, and the like; and an X-ray diffraction map of the crystal form B shows a characteristic diffraction peak in positions of 2 theta(DEG, +/-0.2) 7.7 DEG, 8.3 DEG, 9.6 DEG, 10.0 DEG, 12.3 DEG, 13.8 DEG, 14.9 DEG, 15.8 DEG, 16.8 DEG, 18.3 DEG, 20.5 DEG, 20.8 DEG, 21.5 DEG, 22.7 DEG, 23.4 DEG, 24.3 DEG, 26.8 DEG, 27.0 DEG, 28.3 DEG, 28.9 DEG, 29.8 DEG, and the like. The method comprises the following steps: dissolving, crystallizing, filtering and drying minocycline hydrochloride in a certain amount of mixed solvent of alcohol and water to form minocycline hydrochloride hydrate crystals. The preparation process is simple, and the crystal forms have the advantages of high stability, convenient production, transportation and storage, and the like.
Description
Technical field
The present invention relates to minocycline hydrochloride.Be specifically related to minocycline hydrochloride hydrate crystal forms and preparation method thereof.
Background technology
Minocycline hydrochloride, chemistry is by name: 4, two (dimethylamino)-1,4 of 7-, 4a, 5,5a, 6,11,12a-octahydro-3,10,12,12a-four Oxy-1s, 11-dioxy-2-tetracene carboxamide hydrochloride, molecular formula: C23H27N3O7HCl, its structure is following:
Minocycline HCl (MINOCYCLINE HCL, Minomycin, Minocycline, minocin) is a s-generation tsiklomitsin, is a kind of semi-synthetic tsiklomitsin, is used to treat various light, the grade and moderate infection due to the responsive pathogenic bacteria, and clinical efficacy is better.Because Minocycline HCl has highly lipophilic, and fabulous tissue permeability is arranged, can be distributed widely in each tissue of health and the body fluid, the transformation period also is longer than tsiklomitsin, and Plasma Concentration is high, and sterilizing ability is strong.Simultaneously, this medicine can be almost got rid of from urethra steadily, even decompose, its catabolite is also had an anti-microbial activity, therefore, has efficient, wide spectrum, quick-acting, long-acting, characteristics that oral absorption is fast.It all has certain curative effect at aspects such as dermatosis, urinary system, respiratory tract infection, though certain spinoff is arranged, light than tetracyclines, be a kind of anti-infective that is worthy of popularization.
U.S. Pat 3148212, US3226436, US4948136 have reported the synthetic of Minocycline HCl.Patent WO2008/102161A2 has reported three kinds of crystal formations of Minocycline HCl (alkali) and preparation method thereof.Chinese patent CN02132673.8 has reported freeze-dried minocycline hydrochloride powder injection and preparation method thereof, and CN200710018775.1 has reported minocycline hydrochloride microballoons and preparation method thereof etc.The organic acid salt of Minocycline HCl and Minocycline HCl, inorganic acid salt such as vitriol, trichloroacetate, hydrochloride etc. all can be used as medicinal raw material.Compare with Minocycline HCl (alkali), the hydrochloride of Minocycline HCl, promptly minocycline hydrochloride has better solvability, and what use in present most of preparations such as injection, slow releasing tablet, the dripping pill etc. is minocycline hydrochloride.Therefore good stability is provided, the minocycline hydrochloride of being convenient to produce, transport and store crystal formation helps the use of minocycline hydrochloride.
Summary of the invention
The object of the invention provides minocycline hydrochloride hydrate crystal forms and preparation method thereof, and two kinds minocycline hydrochloride hydrate crystal forms (called after crystal form A and crystal form B) is provided, and has good stability, is convenient to produce, transports and stores.
The present invention provides the hydrate crystal forms A of minocycline hydrochloride, and the X ray diffracting spectrum of said crystal form A is 7.2 ° of 2 θ (°, ± 0.2), 7.8 °, 12.5 °, 12.8 °; 13.9 °, 15.5 °, 17.0 °, 17.5 °, 17.9 °, 18.8 °; 20.0 °, 20.8 °, 21.9 °, 22.3 °, 23.3 °, 24.3 °; 25.0 °, 26.8 °, 27.3 °, 29.5 °, places such as 31.4 ° demonstrate characteristic diffraction peak.Thermogravimetric analysis shows, includes 7.0-8.0% solvent (water) in the said crystal form A, in differential thermal analysis curve, a wide endotherm(ic)peak is arranged about 103 ℃, and 201.9 ℃ have a sharp endotherm(ic)peak.
The crystallography parameter is following:
Crystallographic system: quadrature
Spacer: P212121 (19)
Unit cell parameters:
The present invention provides the hydrate crystal forms B of another kind of minocycline hydrochloride, and the X ray diffracting spectrum of said crystal form B is 7.7 ° of 2 θ (°, ± 0.2), 8.3 °, 9.6 °, 10.0 °; 12.3 °, 13.8 °, 14.9 °, 15.8 °, 16.8 °, 18.3 °; 20.5 °, 20.8 °, 21.5 °, 22.7 °, 23.4 °, 24.3 °; 26.8 °, 27.0 °, 28.3 °, 28.9 °, places such as 29.8 ° demonstrate characteristic diffraction peak.Thermogravimetric analysis shows, includes 15.5-16.5% solvent (water) in the crystal formation, in differential thermal analysis curve, about 110 ℃ and 218 ℃ wide endotherm(ic)peak is arranged.
The crystallography parameter is following:
Crystallographic system: six sides
Spacer: P3121 (152)
Unit cell parameters:
The present invention provides the preparation method of the hydrate crystal forms A of minocycline hydrochloride, is minocycline hydrochloride to be added in the mixed solvent of water with a certain amount of alcohol or alcohol dissolve, and crystallization is filtered, drying, forms a kind of crystal of hydrate A of minocycline hydrochloride.Preparation process is following:
(a) minocycline hydrochloride is joined in alcohol or the alcohol and water, reflux, stirring and dissolving (2-5 hour) forms minocycline hydrochloride solution; The volume ratio of the weight of minocycline hydrochloride and solvent is 1: 10～100 in the said solution;
(b) with the crystallization in 0-5 ℃ ice-water bath of above-mentioned solution;
(c) filtering separation obtains solid, in 35-45 ℃ of following vacuum drying (4-10 hour) drying, gets the minocycline hydrochloride crystalline A.
The present invention provides the preparation method of the crystal form B of another kind of minocycline hydrochloride, be with minocycline hydrochloride with dissolving in a certain amount of alcohol and water, crystallization is filtered, drying, forms a kind of hydrate crystal forms B of minocycline hydrochloride.
Preparation process is following:
(a) minocycline hydrochloride is joined in 10-70% (w/w) alcoholic solution, reflux, stirring and dissolving (2-5 hour) forms minocycline hydrochloride solution; The volume ratio of the weight of minocycline hydrochloride and solvent is 1: 5～80 in the said solution;
(b) with the crystallization in the water-bath of (0-15 ℃) of above-mentioned solution;
(c) filtering separation obtains solid, in 35-45 ℃ of following vacuum drying (4-10 hour) drying, gets minocycline hydrochloride crystallization B.
In the method for preparing the minocycline hydrochloride crystal formation of the present invention, used alcohol is: methyl alcohol, ethanol, propyl alcohol, Ucar 35, Virahol, butanols, butyleneglycol, isopropylcarbinol; Preferably methyl alcohol, ethanol, more preferably methyl alcohol.
Description of drawings
Accompanying drawing 1 is the X-ray powder diffraction collection of illustrative plates (XRD) of minocycline hydrochloride crystal form A;
Accompanying drawing 2 is DTA (DSC) figure of minocycline hydrochloride crystal form A;
Accompanying drawing 3 is thermogravimetric analysis (TGA) figure of minocycline hydrochloride crystal form A;
Accompanying drawing 4 is X-ray powder diffraction collection of illustrative plates (XRD) of minocycline hydrochloride crystal form B;
Accompanying drawing 5 is DTA (DSC) figure of minocycline hydrochloride crystal form B;
Accompanying drawing 6 is thermogravimetric analysis (TGA) figure of minocycline hydrochloride crystal form B;
Embodiment
Embodiment 1:
At room temperature, the 0.5g minocycline hydrochloride is dissolved in 40mL90% (w/w) ethanol reflux; Stirred 2 hours, and treated to dissolve fully clarification and be placed on (0-5 ℃) stirring and crystallizing in the ice-water bath, filter; Vacuum-drying (45 ℃) 8 hours gets minocycline hydrochloride hydrate crystal forms A.
Embodiment 2:
The 10g minocycline hydrochloride is dissolved in 100mL90% (w/w) methyl alcohol, and reflux stirs until dissolving (about 4 hours) fully, and cooling (0-5 ℃) stirring and crystallizing is filtered in the ice-water bath, and vacuum-drying (45 ℃) 8 hours gets minocycline hydrochloride hydrate crystal forms A.
Embodiment 3:
The 1g minocycline hydrochloride is dissolved in 20mL70% (w/w) methyl alcohol, and reflux stirs until dissolving (about 2 hours) fully, slowly cools to 0-5 ℃ of crystallization, filters, and vacuum-drying (40 ℃) 6 hours gets minocycline hydrochloride hydrate crystal forms B.
Embodiment 4:
The 20g minocycline hydrochloride is dissolved in the mixed solvent of 100mL methyl alcohol, 20mL ethanol, 60mL water composition, and reflux stirs; Until dissolving (about 5 hours) fully, be cooled to 10-15 ℃, crystallization; Filter, vacuum-drying (45 ℃) 8 hours gets minocycline hydrochloride hydrate crystal forms B.
Embodiment 5:
The 2g minocycline hydrochloride is dissolved in the mixed solvent of 30mL methyl alcohol, 5mL water composition, and reflux is stirred to dissolving (about 3 hours) fully; Cool off in the 0-5 ℃ of ice-water bath, stirring and crystallizing is filtered; Vacuum-drying (40 ℃) 7 hours gets minocycline hydrochloride hydrate crystal forms A.
Embodiment 6:
The 5g minocycline hydrochloride is dissolved in the mixed solvent of 60mL methyl alcohol, 30mL water composition, and reflux is stirred to solution clarification (about 4 hours); Cooling in the ice-water bath (0-5 ℃), static crystallization filters; Vacuum-drying (45 ℃) 8 hours gets minocycline hydrochloride hydrate crystal forms B.
Claims (4)
1. minocycline hydrochloride hydrate crystal forms A is characterized in that: the X ray diffracting spectrum of said minocycline hydrochloride hydrate crystal forms A, 7.2 ° of 2 θ (°, ± 0.2), 7.8 °, 12.5 °; 12.8 °, 13.9 °, 15.5 °, 17.0 °, 17.5 °, 17.9 °; 18.8 °, 20.0 °, 20.8 °, 21.9 °, 22.3 °, 23.3 °; 24.3 °, 25.0 °, 26.8 °, 27.3 °, 29.5 °; 31.4 ° locate, demonstrate characteristic diffraction peak, include the water of 7.0-8.0% in the crystal formation, in differential thermal analysis curve, a wide endotherm(ic)peak is arranged at 103 ℃, 201.9 ℃ have a sharp endotherm(ic)peak; The crystallography parameter is following:
Crystallographic system: quadrature
Spacer: P212121 (19)
Unit cell parameters: a=7.405; (3)
b=22.315; (8)
c=14.452; (5)
V＝2388.28
Z＝4。
2. method for preparing minocycline hydrochloride hydrate crystal forms A is characterized in that: with the mixed solvent dissolving of minocycline hydrochloride with a certain amount of alcohol or alcohol and water, crystallization is filtered, and drying forms minocycline hydrochloride hydrate crystal forms A, and preparation process is following:
(a) minocycline hydrochloride is joined in alcohol or the alcohol and water, reflux, stirring and dissolving forms minocycline hydrochloride solution; The weight g of minocycline hydrochloride is 1: 10～100 with the volume ml ratio of solvent in the said solution;
(b) with the crystallization in 0-5 ℃ ice-water bath of above-mentioned solution;
(c) filtering separation obtains solid, 35-45 ℃ of following vacuum drying 4-8 hour drying, gets the minocycline hydrochloride hydrate crystalline A.
3. according to the preparation method of the said minocycline hydrochloride hydrate crystal forms A of claim 2, it is characterized in that: described alcohol is methyl alcohol, ethanol, propyl alcohol, Ucar 35, Virahol, butanols, butyleneglycol, isopropylcarbinol a kind or 2 kinds.
4. according to the preparation method of the said minocycline hydrochloride hydrate crystal forms A of claim 3, it is characterized in that: described alcohol is methyl alcohol or ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101527834A CN101693669B (en) | 2009-10-13 | 2009-10-13 | Minocycline hydrochloride hydrate crystal forms and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101527834A CN101693669B (en) | 2009-10-13 | 2009-10-13 | Minocycline hydrochloride hydrate crystal forms and preparation method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210056321.4A Division CN102617396B (en) | 2009-10-13 | 2009-10-13 | Minocycline hydrochloride hydrate crystal form and synthesis method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101693669A CN101693669A (en) | 2010-04-14 |
| CN101693669B true CN101693669B (en) | 2012-08-08 |
Family
ID=42092682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101527834A Expired - Fee Related CN101693669B (en) | 2009-10-13 | 2009-10-13 | Minocycline hydrochloride hydrate crystal forms and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101693669B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT106063B (en) * | 2011-12-19 | 2017-05-30 | Inst Superior Técnico | THERMORRESISTENT CRYSTALLINE MINOCYCLINE PRODUCED BY RECRYSTALLATION WITH CARBON DIOXIDE |
| PT108223B (en) * | 2015-02-13 | 2018-05-08 | Hovione Farm S A | NEW BASE MINOCYCLINE POLYMERIC FORMS AND PROCESSES FOR THEIR PREPARATION |
| CN107954892A (en) * | 2017-12-22 | 2018-04-24 | 宁夏启元药业有限公司 | A kind of method of solvent residual amount in reduction quadracycline |
| CN108218738A (en) * | 2018-03-21 | 2018-06-29 | 宁夏泰瑞制药股份有限公司 | A kind of preparation method of minocycline hydrochloride |
-
2009
- 2009-10-13 CN CN2009101527834A patent/CN101693669B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101693669A (en) | 2010-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101693669B (en) | Minocycline hydrochloride hydrate crystal forms and preparation method thereof | |
| ES2746045T3 (en) | Crystalline form of ertapenem sodium and method of preparation for it | |
| US9018225B1 (en) | Rifaximin crystalline forms and methods of preparation thereof | |
| CN102875531B (en) | A kind of (R)-lansoprazole anhydrous crystal forms and preparation method thereof | |
| CN102838623A (en) | Cefminox sodium compound crystal, preparation method of cefminox sodium compound crystal and sterile powder injection containing cefminox sodium compound crystal | |
| CN103755723B (en) | A kind of preparation method of rifampicin I crystal form | |
| CN102267957A (en) | Method for preparing Febuxostat crystal A | |
| CN102617396B (en) | Minocycline hydrochloride hydrate crystal form and synthesis method thereof | |
| CN101985444B (en) | V crystal form of Fasudil hydrochloride and preparation method and application thereof | |
| CN101347412B (en) | Amifostine trihydrate crystal lyophilized preparation and method of preparing the same | |
| CN101838298A (en) | Clindamycin phosphate solvate crystal and preparation method thereof | |
| CN103923117B (en) | A kind of preparation method who has bioactive schiff bases vanadyl complex crystal | |
| CN102977101A (en) | Doripenem monohydrate, pharmaceutical compositions thereof, preparation method thereof and uses thereof | |
| CN101912370B (en) | D(-)-sulbenicillin disodium powder for injection and preparation process thereof | |
| WO2020244148A1 (en) | Doramectin crystal form a, crystal form b, and preparation method thereof | |
| CN102690300A (en) | Clindamycin phosphate solvate crystal and preparation method thereof | |
| CN102408375B (en) | Ozagrel sodium compound | |
| CN110804080A (en) | Acetaminoavermectin crystal form A, crystal form B, amorphous and preparation method thereof | |
| CN104829467A (en) | Ambroxol hydrochloride dihydrate compound | |
| CN102731430B (en) | Novel febuxostat crystal form, its preparation method and application thereof | |
| CN105985252B (en) | Ornithine aspartate crystal form IV and preparation method thereof | |
| CN102659644A (en) | Crystal forms of 2-aminoethyl sulfonic acid and preparation processes for crystal forms | |
| CN103288893B (en) | Clindamycin Phosphate dimethyl sulfoxide solvent compound crystal and preparation method | |
| CN114957115A (en) | Preparation method of aripiprazole monohydrate with low initial release | |
| WO2017015784A1 (en) | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120808 |